MCID: AMP013
MIFTS: 39

Ampulla of Vater Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ampulla of Vater Cancer

MalaCards integrated aliases for Ampulla of Vater Cancer:

Name: Ampulla of Vater Cancer 12 12 15
Ampulla of Vater Carcinoma 12 15 17
Ampullary Carcinoma 12 58
Malignant Tumour of Ampulla of Vater 12
Carcinoma of the Ampulla of Vater 58
Carcinoma of Ampulla of Vater 12
Ampulloma 58

Characteristics:

Orphanet epidemiological data:

58
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 12 DOID:10020 DOID:4932
ICD9CM 34 156.2
NCIt 49 C3536 C3908
SNOMED-CT 67 93668007
ICD10 32 C24.1
ICD10 via Orphanet 33 C24.1
UMLS via Orphanet 72 C0262401
Orphanet 58 ORPHA300557
UMLS 71 C0153454 C0262401

Summaries for Ampulla of Vater Cancer

MalaCards based summary : Ampulla of Vater Cancer, also known as ampulla of vater carcinoma, is related to ampulla of vater neoplasm and microinvasive gastric cancer. An important gene associated with Ampulla of Vater Cancer is MIR196A1 (MicroRNA 196a-1), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and MicroRNAs in cancer. The drugs Oxaliplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and thyroid, and related phenotype is digestive/alimentary.

Related Diseases for Ampulla of Vater Cancer

Diseases related to Ampulla of Vater Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)
# Related Disease Score Top Affiliating Genes
1 ampulla of vater neoplasm 30.6 KRAS HRAS
2 microinvasive gastric cancer 30.6 MUC6 MUC5AC MIR196A1 CDX2
3 papillary adenocarcinoma 30.6 MUC1 KRT7 KRAS
4 small cell carcinoma 30.5 MUC1 KRT7 KRT20 KRAS CDX2
5 spindle cell carcinoma 30.5 MUC1 KRT7 HRAS
6 cholecystitis 30.4 MUC6 MUC5AC MUC1
7 neuroendocrine carcinoma 30.4 MUC1 KRT7 KRT20
8 adenosquamous carcinoma 30.3 SMAD4 MUC1 KRT7 KRAS
9 in situ carcinoma 30.3 MUC1 KRT17 HRAS
10 familial adenomatous polyposis 30.2 SMAD4 PTGS2 KRAS HRAS
11 ampulla of vater adenocarcinoma 29.9 MUC5AC MUC1 MIR377 MIR30B MIR222 MIR196A1
12 papilloma 29.9 PTGS2 KRT7 KRT20 KRAS
13 gallbladder cancer 29.8 SMAD4 PTGS2 MUC1 MIR145 KRT7 KRAS
14 large intestine cancer 29.7 MIR222 MIR196A1 MIR181A1 MIR145 KRAS HRAS
15 large cell carcinoma 29.7 MUC1 KRT7 KRT20 KRAS HRAS
16 cholangitis, primary sclerosing 29.6 MIR222 MIR145 KRT7
17 tubular adenocarcinoma 29.5 MUC5AC MUC1 KRT7 KRT20 CDX2
18 lynch syndrome 29.5 SMAD4 KRAS HRAS AGR2
19 cystadenoma 29.4 MUC6 MUC5AC MUC1 KRT7 KRT20
20 bladder cancer 29.3 PTGS2 MUC1 MIR222 MIR145 KRT20 KRAS
21 pancreatic ductal adenocarcinoma 29.2 SMAD4 MUC1 MIR222 MIR196A1 MIR145 KRAS
22 intrahepatic cholangiocarcinoma 29.1 SMAD4 MUC5AC MUC1 KRT7 KRT20 KRAS
23 adenoma 29.0 SMAD4 PTGS2 MUC6 MUC5AC MUC1 KRT7
24 pancreatic ductal carcinoma 28.9 SMAD4 MUC6 MUC5AC MUC1 KRT7 KRT20
25 cholangiocarcinoma 28.9 SMAD4 PTGS2 MUC5AC MUC1 KRT7 KRT20
26 adenocarcinoma 28.8 SMAD4 PTGS2 MUC1 KRT7 KRT20 KRAS
27 ovarian serous cystadenocarcinoma 28.7 SMAD4 MUC6 MUC5AC MUC1 MIR196A1 KRAS
28 bile duct cancer 28.7 SMAD4 MUC6 MUC5AC MUC1 KRT7 KRT20
29 signet ring cell adenocarcinoma 28.4 MUC6 MUC5AC MUC1 KRT7 KRT20 KRAS
30 pancreatic adenocarcinoma 28.4 SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR196A1
31 gastric adenocarcinoma 28.2 SMAD4 PTGS2 MUC1 KRT7 KRT20 KRT17
32 pancreatic cancer 27.4 SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR222
33 gastric cancer 27.4 SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR222
34 ovarian cancer 27.4 SMAD4 PTGS2 MUC5AC MUC1 MIR377 MIR222
35 colorectal cancer 26.9 SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR196A1
36 ampulla of vater squamous cell carcinoma 11.5
37 ampulla of vater adenosquamous carcinoma 11.5
38 large cell neuroendocrine carcinoma 10.6
39 bladder signet ring cell adenocarcinoma 10.5 KRT7 CDX2
40 ovary neuroendocrine neoplasm 10.5 KRT7 CDX2
41 anal canal paget's disease 10.5 KRT7 CDX2
42 anal paget's disease 10.5 KRT7 CDX2
43 ureter adenocarcinoma 10.5 KRT7 CDX2
44 adenosquamous colon carcinoma 10.5 KRT7 CDX2
45 anus adenocarcinoma 10.5 KRT7 CDX2
46 mucinous adenofibroma 10.5 KRT7 CDX2
47 scrotum paget's disease 10.5 MUC1 KRT7
48 rectum neuroendocrine neoplasm 10.5 KRT7 CDX2
49 ovarian seromucinous carcinoma 10.5 KRT7 CDX2
50 gallbladder signet ring cell adenocarcinoma 10.5 MUC1 KRT7

Graphical network of the top 20 diseases related to Ampulla of Vater Cancer:



Diseases related to Ampulla of Vater Cancer

Symptoms & Phenotypes for Ampulla of Vater Cancer

MGI Mouse Phenotypes related to Ampulla of Vater Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.23 AGR2 CDX2 HRAS KRAS KRT17 MUC5AC

Drugs & Therapeutics for Ampulla of Vater Cancer

Drugs for Ampulla of Vater Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
2
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
3
Gemcitabine Approved Phase 2 95058-81-4 60750
4
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
5
s 1 (combination) Phase 2
6 Antimetabolites Phase 2
7 Immunologic Factors Phase 2
8 Anti-Infective Agents Phase 2
9 Antiviral Agents Phase 2
10 Immunosuppressive Agents Phase 2
11 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
12 Cola Phase 2
13
Irinotecan Approved, Investigational Phase 1 97682-44-5, 100286-90-6 60838
14
Pancrelipase Approved, Investigational Phase 1 53608-75-6
15 topoisomerase I inhibitors Phase 1
16 Topoisomerase Inhibitors Phase 1
17 pancreatin Phase 1
18
Iodine Approved, Investigational 7553-56-2 807
19 cadexomer iodine

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
2 A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater Completed NCT00354887 Phase 2 Capecitabine;Oxaliplatin
3 A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
4 Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer Completed NCT01587534 Phase 2 Norzyme
5 A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes Not yet recruiting NCT04171700 Phase 2 Rucaparib
6 A Phase II Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients With Advanced Biliary Tract Carcinoma Who Have Failed Prior Chemotherapy Not yet recruiting NCT04003896 Phase 2 Abemaciclib
7 Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
8 Intraluminal Implantation of Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613
9 Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors Unknown status NCT02665494
10 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis Unknown status NCT02656134
11 Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy Unknown status NCT01913275
12 The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan Completed NCT02296736
13 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation. A Prospective Randomized Study Completed NCT02477228
14 Endoscopic Papillectomy for Ampullary Adenomas: an Italian Single Centre Experience Completed NCT03494543
15 to Evaluate the Long-term Results of Endoscopic Papillectomy (EP) Completed NCT01764503
16 Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-Pancreatic Malignancies: A Multicenter Prospective Study Recruiting NCT03494023
17 Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma Recruiting NCT03800212 treatment for ampullary adenocarcinoma
18 Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial Recruiting NCT01844245
19 Periampullary Lesions Via ERCP in Assuit University Hospital Recruiting NCT03185390
20 COMPLICATIONS OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY- AN INDIAN PERSPECTIVE Active, not recruiting NCT04062617

Search NIH Clinical Center for Ampulla of Vater Cancer

Genetic Tests for Ampulla of Vater Cancer

Anatomical Context for Ampulla of Vater Cancer

MalaCards organs/tissues related to Ampulla of Vater Cancer:

40
Colon, Lung, Thyroid, Breast, Pancreas, Ovary, Appendix

Publications for Ampulla of Vater Cancer

Articles related to Ampulla of Vater Cancer:

(show top 50) (show all 103)
# Title Authors PMID Year
1
Influence of bile contamination for patients who undergo pancreaticoduodenectomy after biliary drainage. 61
31885425 2019
2
Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. 61
31127946 2019
3
ASO Author Reflections: The Accurate Prognostic Evaluation and Optimal Treatment Strategy for Ampulla of Vater Carcinoma. 61
31115854 2019
4
[Prediction model for survival in patients with biliary tract cancer: a development and validation study]. 61
31838822 2019
5
Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. 61
31214805 2019
6
Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. 61
30753687 2019
7
Role of systemic inflammation in predicting the prognosis of ampulla of Vater carcinoma. 61
31196491 2019
8
The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma. 61
30790111 2019
9
Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. 61
30645774 2019
10
Incidence and Mortality Rates of Second Pancreatic Cancer Among Survivors of Digestive Cancers: A Nationwide Population-Based Study. 61
30768577 2019
11
Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology. 61
30625267 2019
12
Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. 61
30155920 2019
13
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. 61
30451797 2019
14
Ampulla of Vater carcinoma: Molecular landscape and clinical implications. 61
30487949 2018
15
Sarcomatoid Adenocarcinoma of the Ampulla of Vater. 61
29887717 2018
16
Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. 61
29452703 2018
17
The prognostic impact of differentiation at the invasive front of biliary tract cancer. 61
29572828 2018
18
Ampullary carcinoma-A genetic perspective. 61
29807574 2018
19
Impact of preoperative endoscopic cholangiography and biliary drainage in Ampulla of Vater cancer. 61
29549909 2018
20
Survival rates are higher in married patients with biliary tract cancer: a population-based study. 61
29507708 2018
21
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. 61
27611608 2018
22
PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. 61
28502094 2017
23
Proposed new staging system for ampulla of Vater cancer with greater discriminatory ability: multinational study from eastern and western centers. 61
28660632 2017
24
Impact of delayed gastric emptying after pancreaticoduodenectomy on survival. 61
28547910 2017
25
Genetic alterations in Japanese extrahepatic biliary tract cancer. 61
28693246 2017
26
Bilateral lung metastasectomy in carcinoma of the ampulla of Vater. 61
28168842 2017
27
Metastasectomy for recurrent or metastatic biliary tract cancers: A single center experience. 61
29199665 2017
28
Diet and biliary tract cancer risk in Shanghai, China. 61
28288186 2017
29
Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. 61
27780932 2016
30
KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. 61
27517148 2016
31
Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. 61
27267833 2016
32
The clinical characteristics and manifestations of cytomegalovirus esophagitis. 61
25715747 2016
33
Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. 61
26546182 2016
34
Total Laparoscopic Pancreaticoduodenectomy Using a New Technique of Pancreaticojejunostomy with Two Transpancreatic Sutures with Buttresses. 61
26717322 2016
35
Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. 61
27532258 2016
36
Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. 61
26974670 2016
37
Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. 61
26603157 2015
38
Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. 61
26099746 2015
39
Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. 61
25775067 2015
40
Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. 61
26305204 2015
41
Ampulla of Vater carcinoma in real-world clinical practice: a case series. 61
25908045 2015
42
Salvage radiation therapy for isolated local recurrence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. 61
25319582 2015
43
Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). 61
25628352 2015
44
Variants in motilin, somatostatin and their receptor genes and risk of biliary tract cancers and stones in Shanghai, China. 61
24999450 2014
45
Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. 61
25367337 2014
46
Role of SpyGlass peroral cholangioscopy in the evaluation of indeterminate biliary lesions. 61
24788322 2014
47
Reporting tumor molecular heterogeneity in histopathological diagnosis. 61
25127237 2014
48
Collision tumor of the ampulla of Vater - Coexistence of neuroendocrine carcinoma and adenocarcinoma: report of a case. 61
26155238 2013
49
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. 61
24048674 2013
50
Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. 61
23504585 2013

Variations for Ampulla of Vater Cancer

Expression for Ampulla of Vater Cancer

Search GEO for disease gene expression data for Ampulla of Vater Cancer.

Pathways for Ampulla of Vater Cancer

GO Terms for Ampulla of Vater Cancer

Biological processes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 O-glycan processing GO:0016266 9.43 MUC6 MUC5AC MUC1
2 gene silencing by miRNA GO:0035195 9.43 MIR30B MIR222 MIR196A1 MIR187 MIR181A1 MIR145
3 response to isolation stress GO:0035900 9.16 KRAS HRAS
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 MUC6 MUC5AC MUC1 KRAS HRAS

Molecular functions related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.1 MIR30B MIR222 MIR196A1 MIR187 MIR181A1 MIR145

Sources for Ampulla of Vater Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....